Rivernorth Capital Management’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Rivernorth Capital Management’s Portfolio NKGN Stock Details NKGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-580,432	Closed	-$6.01M	–	515
2023 Q3	$6.01M	Buy	580,432 +74,325	+15%	+$756K	0.31%	71
2023 Q2	$5.23M	Sell	506,107 -976	-0.2%	-$9.99K	0.26%	81
2023 Q1	$5.14M	Hold	507,083	–	–	0.25%	82
2022 Q4	$5.05M	Buy	507,083 +308,565	+155%	+$3.05M	0.23%	90
2022 Q3	$1.94M	Buy	198,518 +1,913	+1%	+$18.7K	0.09%	246
2022 Q2	$1.91M	Hold	196,605	–	–	0.08%	244
2022 Q1	$1.91M	Sell	196,605 -3,385	-2%	-$32.8K	0.07%	247
2021 Q4	$1.94M	Hold	199,990	–	–	0.08%	219
2021 Q3	$1.94M	Buy	+199,990	New	+$1.95M	0.1%	167

Other funds holding NKGN

SIM

Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return

Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

UOC

University of Chicago Chicago, Illinois $323M AUM 14.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Rivernorth Capital Management's NKGN Position: Q4 2023 in Review

Rivernorth Capital Management sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q4 2023, closing a stake of 580,432 shares — an estimated $6.01M sold.

Rivernorth Capital Management first reported a position in NKGN in Q3 2021 and held it in 9 quarters. The position peaked at $6.01M in Q3 2023. 9 funds tracked by Wall St. Rank hold NKGN as of Q4 2023.

Rivernorth Capital Management reported no remaining NKGen Biotech, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Rivernorth Capital Management sold 580,432 NKGen Biotech, Inc. Common Stock shares in Q4 2023, an estimated $6.01M.
Rivernorth Capital Management first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2021 and held it in 9 quarters.
Rivernorth Capital Management's NKGen Biotech, Inc. Common Stock position peaked at $6.01M in Q3 2023.
9 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q4 2023.

Based on Rivernorth Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.